RENAL CELL CARCINOMA (RCC)

This study tests a new drug called GI-108 in people with advanced or metastatic solid tumors (like lung, head and neck, pancreatic, or kidney cancer). The drug is designed to help the immune system fight cancer by targeting a protein called CD73 and delivering a modified immune s…

This study is for people with advanced kidney cancer whose disease is well-controlled after at least a year of combination therapy (immunotherapy plus a targeted drug). Researchers want to see if PET/CT scans can identify who can safely pause treatment without the cancer growing …

This study looks at whether taking cabozantinib less often (skipping doses) works just as well as lowering the dose for people with advanced kidney cancer. About 34 adults who are already on a stable dose will try both methods for 4 weeks each. Researchers will check drug levels …

This study tests a new way to deliver radiation to kidney tumors using advanced imaging to better target the cancer and avoid healthy kidney tissue. The goal is to preserve kidney function as much as possible. About 40 adults with non-spreading kidney cancer will receive this tre…

This study is for people with high-risk kidney cancer that has been removed by surgery. It compares the usual immunotherapy drug (pembrolizumab) alone versus the same drug plus a targeted therapy (tivozanib). The goal is to see if the combination works better at preventing the ca…

This early-stage study tests a new drug called Sapu003 in people with advanced cancers that are sensitive to mTOR treatment, including certain breast cancers, kidney cancer, and liver cancer. The main goal is to find the safest dose and understand side effects. About 27 adults wi…

This study tests a new drug, 177Lu-TLX250, which delivers radiation directly to kidney cancer cells that have a specific marker (CAIX). It is for adults with advanced clear cell kidney cancer that has come back or not responded to at least two prior treatments. The trial compares…

This study is testing a new drug called CTX-10726 in people with advanced cancers (stomach, liver, endometrial, or kidney) that have not responded to standard treatments. The main goal is to check the drug's safety and find the best dose. About 70 participants will receive the dr…

This early-phase study tests a new experimental drug (LB-LR1109) alone or combined with atezolizumab in people with advanced solid tumors, including lung, head and neck, kidney, bladder, and skin cancers. The main goals are to find safe doses and understand side effects. About 76…

This study tests an experimental pill called veonetinib (AL8326) in people with advanced small cell lung cancer, non-small cell lung cancer, or kidney cancer that has come back or spread. The goal is to find the best dose and see if it shrinks tumors. About 80 adults will take pa…

This early-stage trial tests a new drug called XL092, alone or with other immune-boosting drugs, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find safe doses and see if the combination can shrink tumors or slow their gro…

This early-stage study tests a new treatment called CD70-targeted CAR-T cells in people with advanced solid tumors, including kidney, lung, and ovarian cancers. The therapy uses a patient's own immune cells, modified to recognize and attack cancer cells that have a specific marke…

This study tests if a combination of three treatments—a targeted procedure to block blood flow to the tumor, an immunotherapy drug, and a targeted therapy pill—can shrink advanced kidney cancer before surgery. About 40 adults with certain stages of kidney cancer will receive this…

This study compares two ways to remove a kidney: laparoscopic (keyhole) surgery and open surgery. Researchers want to see which method leads to a shorter hospital stay, less blood loss, and lower costs. The study will include 60 people who need a kidney removed due to a non-worki…

This study looks at immune cells in the lymph nodes near kidney tumors to learn how the body fights kidney cancer. Researchers will analyze tissue samples from 10 adult patients to find clues about why some treatments work and others don't. No new treatments are being tested; the…

This study looks back at data from 4700 kidney cancer patients treated between 2012 and 2024. The goal is to create a tool that predicts how the disease will progress, especially for patients with a tumor clot in a vein. Researchers will then test if using this tool to choose tre…